Zhejiang Xianju Pharmaceutical Co., Ltd. (SHE: 002332) and Hangzhou Adamerck Pharmlabs Inc. have entered a tripartite partnership agreement with Aspen Holdings (South Africa), granting the emerging markets pharma leader exclusive promotion rights to aomeikesong in mainland China. The neuromuscular blockade reversal agent, structurally and mechanistically comparable to Merck’s Bridion (sugammadex), will be co-developed and co-commercialized with equal revenue and profit sharing between the Chinese partners.
Revenue Sharing Model: Equal split between Xianju and Adamerck aligns incentives and reduces transaction complexity vs. milestone-heavy structures
Aspen China Positioning: Leverages Aspen’s established anesthesia portfolio (thiopental, propofol) to bundle aomeikesong in perioperative care solutions
Market Context & Competitive Landscape
Factor
Market Implication
China Surgical Volume
>70 million surgeries annually; laparoscopic and robotic procedures requiring deep neuromuscular blockade growing at 15%+ CAGR
Bridion Market
Merck’s sugammadex generated >$1 billion globally; China represents high-growth priority market with limited competition
Neostigmine Dominance
Acetylcholinesterase inhibitors still dominate China due to cost; sugammadex-class agents capturing premium hospital segment
Generic Entry Window
Aomeikesong positions as first credible domestic Bridion alternative with NMPA regulatory pathway clarity
Development & Commercial Outlook
Phase
Activity
Timeline
Current
Partnership execution; technology transfer to Aspen
Q1 2026
Regulatory
NMPA registration submission (if not already filed)
2026
Approval
Marketing authorization for neuromuscular reversal
2026-2027
Launch
Aspen-led hospital promotion with Xianju/Adamerck supply chain
2027
Profit Sharing
Equal revenue and net profit distribution to Xianju and Adamerck
Post-launch
Forward‑Looking Statements This brief contains forward‑looking statements regarding aomeikesong regulatory approval timelines, Aspen’s China commercial execution, and market share capture from Merck’s Bridion. Actual results may differ due to NMPA review delays, competitive pricing from sugammadex, and anesthesia market access dynamics in Chinese tier-1 hospitals.-Fineline Info & Tech
By Fineline Cube